Top

Published in:

Open Access 01-12-2009 | Research

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer

Authors: Na Wei, Stephanie S Liu, Thomas HY Leung, Kar F Tam, Xiao Y Liao, Annie NY Cheung, Karen KL Chan, Hextan YS Ngan

Published in: Molecular Cancer | Issue 1/2009

Abstract

Background

Programmed cell death 4 (Pdcd4) is a novel tumour suppressor and originally identified as a neoplastic transformation inhibitor. The aim of this study was to investigate the expression, prognostic significance and potential function of Pdcd4 in ovarian cancer.

Results

The expression of Pdcd4 was examined in 30 normal ovarian tissues, 16 borderline and 93 malignant ovarian tissues. A continuous down regulation of Pdcd4 expression in the sequence of normal, borderline and malignant tissues was observed. The expressions of Pdcd4 in both ovarian borderline tissues and carcinomas were significantly lower than the expression in normal ovarian tissues (p < 0.001). Furthermore, patients with lower Pdcd4 expressions were found to have shorter disease-free survival (p = 0.037). The expression of Pdcd4 was also assessed by immunohistochemical analysis in 13 ovarian normal tissues and 44 carcinomas. Different subcellular localization of Pdcd4 was observed in normal compared to malignant cells. Predominant nuclear localization of Pdcd4 was found in normal ovarian tissues while ovarian carcinomas showed mainly cytoplasmic localization of Pdcd4.

Conclusion

Our study demonstrated that the loss of Pdcd4 was a common abnormality at molecular level in ovarian cancer and it might be a potential prognostic factor in ovarian cancer patients.

Available only for authorised users

United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. http://www.cdc.gov/uscs

Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S, Colburn NH: Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999, 96: 14037-14042. 10.1073/pnas.96.24.14037PubMedCentralCrossRefPubMed

Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, Colburn NH: A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene. 2001, 20: 669-676. 10.1038/sj.onc.1204137CrossRefPubMed

Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003, 23: 26-37. 10.1128/MCB.23.1.26-37.2003PubMedCentralCrossRefPubMed

Soejima H, Miyoshi O, Yoshinaga H, Masaki Z, Ozaki I, Kajiwara S, Niikawa N, Matsuhashi S, Mukai T: Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet. 1999, 87: 113-114. 10.1159/000015408CrossRefPubMed

Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z: Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999, 49: 1067-1077. 10.1046/j.1440-1827.1999.00995.xCrossRefPubMed

Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, Ozaki I, Petersen I: Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003, 200: 640-646. 10.1002/path.1378CrossRefPubMed

Kang MJ, Ahn HS, Lee JY, Matsuhashi S, Park WY: Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun. 2002, 293: 617-621. 10.1016/S0006-291X(02)00264-4CrossRefPubMed

in Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, Ideguchi H, Yamamoto K, Matsuhashi S: Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 2006, 25: 6101-6112. 10.1038/sj.onc.1209634CrossRef

10.

Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004, 287: C1541-1546. 10.1152/ajpcell.00025.2004CrossRefPubMed

11.

Jansen AP, Camalier CE, Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005, 65: 6034-6041. 10.1158/0008-5472.CAN-04-2119CrossRefPubMed

12.

Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, Goke R: Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol. 2004, 214: 149-153. 10.1016/j.mce.2003.10.058CrossRefPubMed

13.

Bitomsky N, Bohm M, Klempnauer KH: Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 2004, 23: 7484-7493. 10.1038/sj.onc.1208064CrossRefPubMed

14.

Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 2007, 26: 4550-4562. 10.1038/sj.onc.1210234CrossRefPubMed

15.

Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, Tan TH, Colburn NH: Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006, 26: 1297-1306. 10.1128/MCB.26.4.1297-1306.2006PubMedCentralCrossRefPubMed

16.

Jansen AP, Camalier CE, Stark C, Colburn NH: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 2004, 3: 103-110.PubMed

17.

Kalinichenko SV, Kopantzev EP, Korobko EV, Palgova IV, Zavalishina LE, Bateva MV, Petrov AN, Frank GA, Sverdlov ED, Korobko IV: Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors. Lung Cancer. 2008, 62: 173-180. 10.1016/j.lungcan.2008.03.022CrossRefPubMed

18.

Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H: Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007, 110: 1697-1707. 10.1002/cncr.22983CrossRefPubMed

19.

Wang X, Wei Z, Gao F, Zhang X, Zhou C, Zhu F, Wang Q, Gao Q, Ma C, Sun W: Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res. 2008, 28: 2991-2996.PubMed

20.

Goke R, Gregel C, Goke A, Arnold R, Schmidt H, Lankat-Buttgereit B: Programmed cell death protein 4 (PDCD4) acts as a tumor suppressor in neuroendocrine tumor cells. Ann N Y Acad Sci. 2004, 1014: 220-221. 10.1196/annals.1294.024CrossRefPubMed

21.

Bitomsky N, Wethkamp N, Marikkannu R, Klempnauer KH: siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression. Oncogene. 2008, 27: 4820-4829. 10.1038/onc.2008.115CrossRefPubMed

22.

Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, Colburn NH: Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008, 68: 1254-1260. 10.1158/0008-5472.CAN-07-1719CrossRefPubMed

23.

Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M: S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006, 314: 467-471. 10.1126/science.1130276CrossRefPubMed

24.

Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y: Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 2005, 65: 11282-11286. 10.1158/0008-5472.CAN-05-3469CrossRefPubMed

25.

Lankat-Buttgereit B, Lenschen B, Schmidt H, Goke R: The action of Pdcd4 may be cell type specific: evidence that reduction of dUTPase levels might contribute to its tumor suppressor activity in Bon-1 cells. Apoptosis. 2008, 13: 157-164. 10.1007/s10495-007-0153-xCrossRefPubMed

26.

Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH: The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene. 2003, 22: 4905-4910. 10.1038/sj.onc.1206710CrossRefPubMed

Title: Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Authors: Na Wei
Stephanie S Liu
Thomas HY Leung
Kar F Tam
Xiao Y Liao
Annie NY Cheung
Karen KL Chan
Hextan YS Ngan
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-8-70

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells

PTEN inhibits BMI1 function independently of its phosphatase activity

Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups

Identification of novel Notch target genes in T cell leukaemia

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer